Doctor of Philosophy, The Ohio State University, 2023, Chemical Engineering
Minimal residual disease (MRD) is the persistence of latent cancer cells in distant sites originating from a primary tumor. In the case of breast cancer, the tumor cells originate in the breast tissue, such as the lobules or the ducts, traverse circulation, and invade distant organs, such as the liver, lung, bones, and brain, which are considered traditional metastatic sites. While treating cancerous cells in the primary site has encouraging survival rates of ~ 99%, once cancer metastasizes to distant organs, the survival rates plummet to ~ 30%. The drastic decrease in survival is due to the biological differences of the cancer cells responsible for MRD, such as evasion of the immune system, drug resistance, and dormancy, whereby the latter is characterized as the cessation of proliferation by cell cycle arrest. The extracellular matrix (ECM) and intercellular communication have been associated with the induction of dormancy. Furthermore, extracellular vesicles (EVs), which are cell-derived nanoparticles, are carriers of bioactive molecules and are thus a part of intercellular communication systems. Therefore, engineering the tumor microenvironment to actuate cell-ECM and cell-cell interactions has profound implications for understanding and simplifying the complexity of cancer dormancy. Herein, we present novel in vitro methods for engineering the tumor microenvironment to promote intercellular interaction, provide physiologically relevant models for EV secretion, develop novel methods to phenotype blood-derived particles, delineate a signature for dormant tumor cells, and efficiently screen therapies that target the inherent biology of tumor cells.
Committee: Eduardo Reátegui Ph.D. (Advisor); Bhuvaneswari Ramaswamy M.D., M.R.C.P. (Committee Member); Andre F. Palmer Ph.D. (Committee Member); Natarajan Muthusamy Ph.D., D.V.M. (Committee Member)
Subjects: Chemical Engineering